A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma (Protocol No. P08067)
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Schering-Plough
- 12 Oct 2015 Results published in the Annals of Allergy, Asthma and Immunology
- 23 Oct 2012 Primary endpoint 'Rhinoconjunctivitis-Symptom-Medication-Score' has been met according to an ALK Abello media release.
- 07 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.